6533b826fe1ef96bd12846d6
RESEARCH PRODUCT
Combination chemotherapy with cyclophosphamide, doxorubicin and vincristine in the treatment of stage III-IV small-cell lung cancer.
Vittorio GebbiaSergio PalmeriNicolo' GebbiaAntonio RussoLuciano Rausasubject
MaleVincristinemedicine.medical_specialtyLung NeoplasmsCyclophosphamideGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Stage (cooking)Carcinoma Small CellLung cancerCyclophosphamideAgedNeoplasm StagingPharmacologybusiness.industryNeurotoxicityCombination chemotherapyMiddle Agedmedicine.diseaseSurgerySurvival RateInfectious DiseasesOncologyCyclophosphamide/doxorubicinDoxorubicinVincristineFemaleNon small cellbusinessmedicine.drugFollow-Up Studiesdescription
SummaryTwenty patients with histologically confirmed small-cell lung cancer were treated with cyclophosphamide 1000 mg/m2 i.v. on day 1, vincristine 1.4 mg/m2 i.v. day 1, and adriamycin 50 mg/m2 i.v. on day 1. This protocol was repeated every 21 days. Out of 17 evaluable patients 2 obtained a complete response (12%) with a mean duration of 11 months, 4 patients achieved a partial response with a mean duration of 6.3 + months, and 1 had a minimal response of 7.2 months. Two patients had a stabilization which lasted a mean of 4 + months, while 8 patients progressed. Although the mean survival was higher in responders than in non-responders, the difference in survival time was not statistically significant. The treatment was quite well tolerated with hematological toxicity in 78% of cases, oral and gastrointestinal toxicity in 83%, alopecia in 78%, and neurotoxicity in 16% of cases.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1989-10-01 | Journal of chemotherapy (Florence, Italy) |